All In Biotech

Drug Trial Radar · NCT07109297

Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India

A Phase 4, Open-label, Single-arm Clinical Study to Describe Safety and Efficacy Outcomes Associated With the Use of Nirsevimab in Neonates and Infants Born During or Entering Their First Respiratory Syncytial Virus (RSV) Season and in Children up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

110

Actual

Start

Jul 31, 2025

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 months, up to 24 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Conditions

  • RSV Immunization

Interventions

  • NirsevimabBiological

    Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of immediate adverse events (AEs)Time frame: Within 30 minutes after immunization
  2. Presence of non-serious AEsTime frame: From Day 01 through Day 31
  3. Presence of adverse events of special interest (AESIs) throughout the studyTime frame: Throughout the study (approximately 6 months)
  4. Presence of medically attended adverse events (MAAEs) throughout the studyTime frame: Throughout the study (approximately 6 months)
  5. Presence of serious adverse events (SAEs) throughout the studyTime frame: Throughout the study (approximately 6 months)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 3560002

    Bengaluru, India

  • Investigational Site Number : 3560008

    Jaipur, India

  • Investigational Site Number : 3560003

    Kolkata, India

  • Investigational Site Number : 3560007

    Nagpur, India

  • Investigational Site Number : 3560001

    New Delhi, India

  • Investigational Site Number : 3560004

    Pune, India

  • Investigational Site Number : 3560006

    Vizianagaram, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.